Cargando…

Impact of Effective Intravesical Therapies on Quality of Life in Patients with Non-Muscle Invasive Bladder Cancer: A Systematic Review

Background: Conventional and newly emerged intravesical modalities have demonstrated prophylactic effectiveness that may improve quality of life (QoL) in non-muscle invasive bladder cancer. The purpose of this study is to analyze existing QoL evidence in patients receiving any form of intravesical t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yuen, John W., Wu, Ricky W., Ching, Shirley S., Ng, Chi-Fai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9518426/ https://www.ncbi.nlm.nih.gov/pubmed/36078542 http://dx.doi.org/10.3390/ijerph191710825

Ejemplares similares

Intravesical chemotherapy in non-muscle-invasive bladder cancer
por: Porten, Sima P., et al.
Publicado: (2015)

The Future of Intravesical Drug Delivery for Non-Muscle Invasive Bladder Cancer
por: Douglass, Laura, et al.
Publicado: (2016)

Device-assisted intravesical therapy for non-muscle invasive bladder cancer
por: Hendricksen, Kees
Publicado: (2019)

Intravesical Chemohyperthermia vs. Bacillus Calmette-Guerin Instillation for Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis
por: Zhao, Hongda, et al.
Publicado: (2021)

Intravesical gemcitabine for non-muscle invasive bladder cancer: An abridged Cochrane Review
por: Han, Mi Ah, et al.
Publicado: (2021)

Efficacy of Bladder Intravesical Chemotherapy with Three Drugs for Preventing Non-Muscle-Invasive Bladder Cancer Recurrence
por: Zhang, Jianglei, et al.
Publicado: (2021)

Intravesical Gemcitabine versus Intravesical Bacillus Calmette–Guérin for the Treatment of Non-Muscle Invasive Bladder Cancer: An Evaluation of Efficacy and Toxicity
por: Prasanna, Thiru, et al.
Publicado: (2017)

Sequential Intravesical Gemcitabine and Docetaxel for the Salvage Treatment of Non-Muscle Invasive Bladder Cancer
por: Steinberg, Ryan L., et al.
Publicado: (2015)

Hyperthermic Intravesical Chemotherapy for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients
por: de Jong, Joep J., et al.
Publicado: (2018)

Novel intravesical therapeutics in the treatment of non-muscle invasive bladder cancer: Horizon scanning
por: Ward, Kelly, et al.
Publicado: (2022)

Intravesical chemotherapy for intermediate risk non-muscle invasive bladder cancer recurring after a first cycle of intravesical adjuvant therapy
por: Serretta, Vincenzo, et al.
Publicado: (2015)

Impact of intravesical Bacillus Calmette-Guérin and chemotherapy on the bladder microbiome in patients with non-muscle invasive bladder cancer
por: James, Christopher, et al.
Publicado: (2023)

The Role of Adjuvant Single Postoperative Instillation of Gemcitabine for Non-Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis
por: Koimtzis, Georgios, et al.
Publicado: (2022)

Oncological Outcomes of Sequential Intravesical Gemcitabine and Docetaxel in Patients with Non-Muscle Invasive Bladder Cancer
por: Milbar, Niv, et al.
Publicado: (2017)

Redefining the role of immediate intravesical instillation of mitomycin C in non-muscle invasive bladder cancer
por: Batura, Deepak
Publicado: (2018)

Adjuvant Hyperthermic Intravesical Chemotherapy in Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer
por: Magalhães, Joana C, et al.
Publicado: (2023)

Hyperthermic intravesical chemotherapy with mitomycin‐C for the treatment of high‐risk non‐muscle‐invasive bladder cancer patients
por: Conroy, Samantha, et al.
Publicado: (2022)

Intravesical immunotherapy in nonmuscle invasive bladder cancer
por: Jokisch, Jan-Friedrich, et al.
Publicado: (2015)

Oncolytic immunotherapy for the treatment of non-muscle invasive bladder cancer using intravesical coxsackievirus A21
por: Annels, Nicola E, et al.
Publicado: (2015)

High-Risk Non-Muscle-Invasive Bladder Cancer—Therapy Options During Intravesical BCG Shortage
por: Veeratterapillay, Rajan, et al.
Publicado: (2016)

Editorial on the value of an immediate intravesical instillation of mitomycin C in patients with non-muscle-invasive bladder cancer
por: Oosterlinck, Willem, et al.
Publicado: (2018)

Emerging concepts and spectrum of renal injury following Intravesical BCG for non-muscle invasive bladder cancer
por: Mohammed, Azharuddin, et al.
Publicado: (2017)

Renal Granulomatosis Post Intravesical Bacillus Calmette–Guerin Therapy for Non-muscle-invasive Bladder Cancer
por: Tran-Harding, Karen, et al.
Publicado: (2018)

The optimal intravesical maintenance chemotherapy scheme for the intermediate-risk group non-muscle-invasive bladder cancer
por: Chen, Jian-Xin, et al.
Publicado: (2023)

The Role of Fluorescence In Situ Hybridization in the Surveillance of Non-Muscle Invasive Bladder Cancer: An Updated Systematic Review and Meta-Analysis
por: Zheng, Weitao, et al.
Publicado: (2022)

TERT C228T mutation in non‐malignant bladder urothelium is associated with intravesical recurrence for patients with non‐muscle invasive bladder cancer
por: Hayashi, Yujiro, et al.
Publicado: (2020)

Non-Invasive Imaging Modalities in Intravesical Murine Models of Bladder Cancer
por: Relouw, Sydney, et al.
Publicado: (2023)

Study protocol of a phase II clinical trial of oral metformin for the intravesical treatment of non-muscle invasive bladder cancer
por: Molenaar, Remco J., et al.
Publicado: (2019)

Evaluating the efficacy and safety of intravesical chemotherapies for non-muscle invasive bladder cancer: a network meta-analysis
por: Zhuo, Chuanjun, et al.
Publicado: (2016)

Long-Term Experience with Radiofrequency-Induced Hyperthermia Combined with Intravesical Chemotherapy for Non-Muscle Invasive Bladder Cancer
por: Brummelhuis, Iris S. G., et al.
Publicado: (2021)

Efficacy and toxicity of intravesical Bacillus Calmette-Guérin therapy in elderly patients with non-muscle-invasive bladder cancer
por: Matsuoka, Yuki, et al.
Publicado: (2021)

Intravesical docetaxel for high-risk non-muscle invasive bladder cancer after Bacillus Calmette-Guérin failure
por: Shantharam, Govind, et al.
Publicado: (2021)

Intravesical BCG in patients with non-muscle invasive bladder cancer induces trained immunity and decreases respiratory infections
por: van Puffelen, Jelmer H, et al.
Publicado: (2023)

PemBla: A Phase 1 study of intravesical pembrolizumab in recurrent non‐muscle‐invasive bladder cancer
por: Woodcock, Victoria K., et al.
Publicado: (2023)

Intravesical gemcitabine versus mitomycin for non-muscle invasive bladder cancer: a systematic review and meta-analysis of randomized controlled trial
por: Li, Rongxin, et al.
Publicado: (2020)

Efficacy of intravesical therapies on the prevention of recurrence and progression of non‐muscle‐invasive bladder cancer: A systematic review and network meta‐analysis
por: Lu, Jun‐Lin, et al.
Publicado: (2020)

Clinical efficacy of intravesical gemcitabine combined with ubenimex in patients with non-muscle-invasive bladder carcinoma after transurethral resection of bladder tumor
por: Shao, Li-jun, et al.
Publicado: (2022)

Initial experience with surrounding en bloc transurethral resection of bladder tumor and simultaneous intravesical treating for non-muscle invasive bladder cancer
por: Teng, Lichen, et al.
Publicado: (2022)

AB057. Intravesical laparoscopic harvest of bladder mucosa for urethroplasty
por: Ho, Son Fat, et al.
Publicado: (2015)

Neoadjuvant systemic and intravesical chemotherapy with partial cystectomy for muscle invasive bladder cancer with concomitant CIS
por: Plambeck, Benjamin D., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_e54moonijs692r2gpjg3rp914g